Article
Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Proceedings of the National Academy of Sciences of the United States of America - 30 Aug 2022
Evans Rebecca, Kimura Haruhide, Alexander Robert, Davies Ceri H, Faessel Hélène, Hartman Deborah S, Ishikawa Takashi, Ratti Emiliangelo, Shimizu Kohei, Suzuki Motohisa, Tanaka Shinichiro, Yukitake Hiroshi, Dauvilliers Yves, Mignot Emmanuel
Abstract excerpt
Narcolepsy type 1 (NT1) is a sleep disorder caused by a loss of orexinergic neurons. Narcolepsy type 2 (NT2) is heterogeneous; affected individuals typically have normal orexin levels. Following evaluation in mice, the effects of the orexin 2 receptor (OX2R)-selective agonist danavorexton were evaluated in single- and multiple-rising-dose studies in healthy adults, and in individuals with NT1 and NT2. In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.